PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort
← catalyst calendarNCT07560215 · readout in 224 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
100estimated
Sites
1
Country
Brazil
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-30 | estimated | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Prostate Cancer
Intervention
- Diagnostic test: Archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.
Primary outcomes
what the primary-completion date above is the date OFprevalence of HRR mutations in tissue and/or liquid biopsy samples
measured april 2026 to april 2027
prevalence of PTEN loss of expression in tissue samples
measured april 2026 to april 2027
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed